Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12-71), 23% (95% CI: -11-48) and 5% (95% CI: -92-56) among those with symptom onset 1-5, 6-11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.
Authors
- Ivan Mlinarić (ORCID: https://orcid.org/0009-0008-8546-6331)
- Silke Buda (ORCID: https://orcid.org/0000-0003-3448-3357)
- Mariëtte Hooiveld (ORCID: https://orcid.org/0000-0002-5513-1740)
- Mihaela Lazăr (ORCID: https://orcid.org/0000-0002-8226-6026)
- Marlena C. Kaczmarek (ORCID: https://orcid.org/0000-0002-5556-276X)
- Marine Maurel (ORCID: https://orcid.org/0000-0002-5478-4045)
- Verónica Gomez (ORCID: https://orcid.org/0000-0003-0485-0005)
- Nuno Verdasca (ORCID: https://orcid.org/0000-0002-4673-5411)
- Gergő Túri (ORCID: https://orcid.org/0000-0003-3465-8321)
- Tove Samuelsson Hagey
- Esther Kissling (ORCID: https://orcid.org/0000-0001-7188-8404)
- Marie‐Anne Rameix‐Welti (ORCID: https://orcid.org/0000-0002-5901-3856)
- Ana Paula Rodrigues (ORCID: https://orcid.org/0000-0003-2264-4723)
- Frederika Dijkstra (ORCID: https://orcid.org/0000-0003-0012-740X)
- Adam Meijer (ORCID: https://orcid.org/0000-0001-8074-7582)
- Daniel Castrillejo (ORCID: https://orcid.org/0000-0002-6485-9039)
- Aryse Melo (ORCID: https://orcid.org/0000-0002-6655-8715)
- Sanja Filipović (ORCID: https://orcid.org/0000-0001-8166-8042)
- Lore Merdrignac (ORCID: https://orcid.org/0000-0001-6307-3192)
- Beatrix Oroszi (ORCID: https://orcid.org/0000-0001-8915-0336)
- Ralf Dürrwald (ORCID: https://orcid.org/0000-0002-3432-0438)
- Charlotte Lanièce Delaunay (ORCID: https://orcid.org/0000-0002-7038-325X)
- Sabrina Bacci (ORCID: https://orcid.org/0000-0002-6575-3439)
- Charlene Bennett
- Lorena Vega‐Piris (ORCID: https://orcid.org/0000-0001-9781-9626)
- Joan O’Donnell (ORCID: https://orcid.org/0000-0002-2838-9762)
- Neus Latorre‐Margalef (ORCID: https://orcid.org/0000-0001-9616-2693)
- Camino Trobajo‐Sanmartín (ORCID: https://orcid.org/0000-0001-5105-252X)
- Noémie Sève
- Iván Martínez‐Baz (ORCID: https://orcid.org/0000-0002-3405-2277)
Institutions
- University College Dublin (IE)
- Semmelweis University (HU)
- Public Health Agency of Sweden (SE)
- Inserm (FR)
- Institut Pasteur (FR)
- Digital Curation Centre (GB)
- Université Paris Cité (FR)
- Robert Koch Institute (DE)
- Université Paris-Saclay (FR)
- Instituto de Salud Carlos III (ES)
- Health Service Executive (IE)
- Sorbonne Université (FR)
- Instituto de Salud Pública de Navarra (ES)
- Hrvatski zavod za javno zdravstvo (HR)
- National Institute for Public Health and the Environment (NL)
- Netherlands Institute for Health Services Research (NL)
- Health Protection Surveillance Centre (IE)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- National Institute of Health Dr. Ricardo Jorge (PT)
- Consejería de Salud y Consumo (ES)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
- Infection et inflammation (FR)
- European Centre for Disease Prevention and Control (SE)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1111/irv.70009
- Citations
- 13
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 5.06
Funders
- Irish College of General Practitioners
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Health Service Executive
- European Centre for Disease Prevention and Control
- Public Health Agency
- University College Dublin
- Institut National de la Santé et de la Recherche Médicale
- Semmelweis Egyetem
- Université Paris-Saclay
- Folkhälsomyndigheten
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
- Sorbonne Université
- Robert Koch Institut
- Instituto de Salud Carlos III
- Rijksinstituut voor Volksgezondheid en Milieu
- National Research, Development and Innovation Office